T1	Treatment 0 11	Eltrombopag
T2	Treatment 121 132	Eltrombopag
T3	Treatment 139 175	oral thrombopoietin receptor agonist
T4	Treatment 262 288	eltrombopag versus placebo
T5	Treatment 409 427	placebo-controlled
T6	Treatment 672 676	plus
T7	Treatment 680 714	mg eltrombopag or matching placebo
T8	Treatment 1319 1357	response to eltrombopag versus placebo
T9	Treatment 1623 1652	(135 eltrombopag, 62 placebo)
T10	Treatment 1673 1691	in the eltrombopag
T11	Treatment 1855 1873	in the eltrombopag
T12	Treatment 1900 1914	in the placebo
T13	Treatment 2030 2051	receiving eltrombopag
T14	Treatment 2108 2117	receiving
T15	Treatment 2156 2177	receiving eltrombopag
T16	Treatment 2234 2243	receiving
T17	Treatment 2275 2305	patients receiving eltrombopag
T18	Treatment 2354 2362	patients
T19	Treatment 2373 2374	.
T20	Treatment 2375 2404	Nine (7%) eltrombopag-treated
T21	Treatment 2422 2433	(3%) in the
T22	Treatment 2510 2543	and five (4%) eltrombopag-treated
T23	Treatment 2562 2571	allocated
T24	Treatment 2628 2643	patients taking
T25	Treatment 2713 2737	treated with eltrombopag
T26	Treatment 2739 2765	INTERPRETATION Eltrombopag
T27	Treatment 3000 3027	associated with eltrombopag
